for people ages 18 years and up (full criteria)
at UC Davis
study started
estimated completion



This study will evaluate the safety, tolerability, antiretroviral activity, and pharmacokinetics of 3 doses of islatravir (MK-8591) in combination with doravirine (DOR) and lamivudine (3TC) administered to antiretroviral treatment-naïve adult participants with human immunodeficiency virus type 1 (HIV-1) infection.

Official Title

A Phase 2B, Randomized, Double-Blind, Active-Comparator-Controlled, Dose-Ranging Clinical Trial to Evaluate the Safety, Tolerability, Antiretroviral Activity, and Pharmacokinetics of MK-8591 Given in Combination With Doravirine (DOR) and Lamivudine (3TC) in HIV-1-Infected Treatment-Naïve Adults


HIV-1 Infection Tenofovir Lamivudine 4'-ethynyl-2-fluoro-2'-deoxyadenosine Islatravir Doravirine Doravirine, Tenofovir, Lamivudine Doravirine/Islatravir Islatravir 0.25 mg Islatravir 0.75 mg Islatravir 2.25 mg


You can join if…

Open to people ages 18 years and up

  • Has HIV-1 infection
  • Is naïve to anti-retroviral therapy (ART).
  • Is clinically stable, with no signs or symptoms of acute infection, at the time of entry into the study
  • Female is not pregnant, not breastfeeding, not a woman of childbearing potential (WOCBP); but if WOCBP agrees to follow the contraceptive guidance
  • All participants, male and female, agree to use barrier methods of contraception when engaged in any sexual activity during treatment and for 6 weeks following treatment.

You CAN'T join if...

  • Is a user of recreational or illicit drugs or has had a history of drug or alcohol abuse or dependence that may interfere with trial participation
  • Has significant hypersensitivity or other contraindication to any of the components of the study drugs
  • Has a history of malignancy ≤5 years prior
  • Female expects to donate eggs at any time during the study
  • Is breastfeeding or expecting to conceive
  • A WOCBP who has a positive urine pregnancy test on Day 1 before the first dose of study treatment
  • Has been treated for a viral infection other than HIV-1, such as hepatitis B, with an agent that is active against HIV-1
  • Has used systemic immunosuppressive therapy or immune modulators within 30 days prior to treatment in this study or is anticipated to need them during the course of the study
  • Requires any of the following prohibited medications: Carbamazepine, Phenobarbital, Phenytoin, Rifabutin, Rifampin, Herbal remedies, St. John's Wort, Modafinil, Bosentan, Nafcillin, Pentostatin
  • Is currently participating in or has participated in an interventional clinical trial with an investigational compound or device within 30 days of signing informed consent to participate in this current trial
  • Has a documented or known virologic resistance to any approved HIV-1 reverse transcriptase inhibitor, protease inhibitor, integrase inhibitor
  • Has active hepatitis C virus (HCV) coinfection defined as detectable HCV RNA or HBV co-infection defined as hepatitis B surface antigen [HBsAg]-positive
  • Has a current (active) diagnosis of acute hepatitis due to any cause
  • Has previously been randomized in a study and received islatravir (MK-8591), DOR, Doravirine, Tenofovir, Lamivudine, or 3TC.


  • University California / Davis ( Site 0101)
    Sacramento California 95817 United States
  • Pueblo Family Physicians ( Site 0119)
    Phoenix Arizona 85015 United States


in progress, not accepting new patients
Start Date
Completion Date
Merck Sharp & Dohme Corp.
Phase 2
Study Type
Last Updated